Juvenile Idiopathic Arthritis

 Overview On Juvenile Idiopathic Arthritis: Diagnosis and Treatment

Daniel Krichker.

Abstract:

Rheumatoid Arthritis is a progressive auto-immune disease. This chronic illness, though most prominent in children, is widespread around the US and the world. Around 1.3 million people in the United States have RA, representing 0.6 to 1% of the population. The Arthritis Foundation (AF) estimates that the global prevalence of RA is 0.5%-1% in developed countries. Just under 300,000 children have juvenile idiopathic arthritis, according to the NLM. That's about 1 to 2 in 1,000 children, per the Arthritis Foundation. Even though JIA is so common among children, it mostly affects females (75% of Juvenile Idiopathic Arthritis patients are female.) Juvenile Idiopathic Arthritis involves inflammation of the synovium and destruction of tissues in joints. Juvenile Idiopathic Arthritis could lead to pericarditis and pleuritis. It is challenging to diagnose Juvenile Idiopathic Arthritis in children because there is no existing blood test that could detect Juvenile Idiopathic Arthritis. JIA is not just detrimental to children just because of its effect on joints. The medication that children take makes the children immunosuppressed, making them much more vulnerable to infections and diseases.such as squamous cell carcinoma (SCC), melanoma, Kaposi's sarcoma, and Covid 19. Doctors can test for Erythrocyte sedimentation rate, C-reactive protein, HLA-B27, anti-cyclic citrullinated peptide (CCP) antibodies, etc. However, these tests can only hint at JIA, because none of the tests bring back indefinite and constant results. The main goal of therapy in juvenile idiopathic arthritis is the suppression of clinical symptoms (swelling, limps,etc). The pharmacological approach includes use of medications like DMARDs, NSAIDs etc. and non-pharmacological approach includes physiotherapy, which helps in restoring normal joint function and herbs as adjuvants which has the benefit of no side effects. Overall, there is no cure for JIA, only suppressive and deleterious medications.

Objective: This article will outline the diagnosis and treatments of juvenile idiopathic arthritis, supported by multiple credible sources and research. This article is written in hope to spread awareness and information about patients with juvenile idiopathic arthritis.

Introduction

 Background

JIA is characterized by persistent joint inflammation lasting for more than six weeks in individuals under the age of 16, with an onset before the age of 16 and exclusion of other known causes of arthritis. JIA is a heterogeneous (consisting of dissimilar elements) condition with varying clinical presentations, disease courses, and prognoses. The effects of JIA can be significant and wide-ranging, impacting various aspects of a child's life. Joint involvement is prominent in JIA, with symptoms such as joint pain, swelling, stiffness, joint deformity. The disease can affect one or multiple joints, leading to functional impairment, physical disability, and deformities. The joints commonly affected in JIA include (but not limited to) the knees, ankles, wrists, and small joints of the hands and feet. The disease can also involve the jaw, neck, spine, and hips.

Significance of Studies

JIA is the most common chronic rheumatic disease in children, affecting a significant number of individuals worldwide. By conducting a study on its diagnosis and treatment, we can improve our understanding of the condition and its impact on affected children, their families, and society as a whole. Furthermore, studies on diagnosis can help identify key clinical features, biomarkers, and diagnostic tools that aid in early identification of JIA, leading to prompt treatment and improved prognosis. Moreover, by studying treatment strategies, people can identify the effective pharmacological and non-pharmacological interventions, optimize medication regimens, and develop personalized treatment plans. Finally, JIA can have a significant impact on the physical, emotional, and social well-being of affected children and their families. By investigating the diagnosis and treatment of JIA, we can gain insights into the psychosocial aspects of the condition, including its impact on quality of life, educational needs, mental health, and social participation. 

Classification of Juvenile Idiopathic Arthritis

Systemic-Onset Juvenile Idiopathic Arthritis

About 10% to 20% of children with Juvenile Idiopathic Arthritis have a rare subtype called systemic juvenile idiopathic arthritis (SJIA). Systemic Juvenile Idiopathic Arthritis is more severe than the general type of Juvenile Idiopathic arthritis because it not only affects the joins, but other parts of the body, including the liver, lungs, and heart. SJIA(also known as Still’s disease), can occur any time during childhood, but it most commonly starts at about two years of age. This disease is gender objective- girls and boys are affected equally. SJIA also differs from other subtypes in that it’s the only one considered an autoinflammatory (problems with the innate immune system’s reactions) rather than autoimmune disease (Conditions where the immune system mistakenly attacks healthy body cells). SJIA is more difficult to diagnose than Juvenile Idiopathic Arthritis, partly due to the difference of symptoms. It is a lifelong disease for many patients and can continue into adulthood. Systemic-onset juvenile idiopathic arthritis can be treated with nonsteroidal antiinflammatory drugs. If NSAIDs are not effective, glucocorticoids and methotrexate may be used.

Image 1:

(Refers to image 1).

1, Cutaneous involvement is one of the key extra-articular factors in systemic JIA. The exanthem or rash presents as discrete, salmon-pink macules, or oedematous papules that are typically transient and coincide with fevers. These tend to occur on the trunk, axillae, and proximal extremities but are not commonly seen on the palms, soles, or the face.

Oligoarticular Juvenile Idiopathic Arthritis

Oligoarticular juvenile idiopathic arthritis is a subtype of juvenile idiopathic arthritis. Oligoarticular juvenile idiopathic arthritis is the most prevalent juvenile idiopathic arthritis subtype. It makes up around half of all the idiopathic arthritis patients in North America and Europe. Usually, with the onset of oligoarticular juvenile idiopathic arthritis, there is asymmetric joint involvement that affects two large joints (such as the knee). Systemic symptoms (e.g., fever, rash) are scarce. Pain in a juvenile victim of OJIA is subtle. A  parent may notice that their child has a limp, a reluctance to walk or run, or swelling of the affected joint. The treatment of extended oligoarticular juvenile idiopathic arthritis is much like that of rheumatoid factor positive or rheumatoid factor negative polyarticular juvenile idiopathic arthritis. The similarity in treatment is due to the polyarticular (many joins affected) involvement. Such as in the case of my sister, a patient will receive prescribed methotrexate if intra-articular steroid injections are insufficient.

Polyarticular Juvenile Idiopathic Arthritis

Polyarticular juvenile idiopathic arthritis is a subset of juvenile idiopathic arthritis (JIA) that is defined by the presence of more than four affected joints during the first six months of illness. Children with polyarticular arthritis may start out with arthritis in only one or two joints, and then increase to more than five. Or they may get arthritis in many joints all at once. Some of the main symptoms include anemia, enlarged liver, joint damage, inflammation, etc. The treatment of polyarticular juvenile idiopathic arthritis is similar to that of the other subsets of juvenile arthritis. The specialist would start with non-steroidal anti-inflammatory drugs. If these drugs prove insufficient, the specialist would move on to systemic drugs. However, non-steroidal anti-inflammatory drugs are usually the first step to all treatments.

Image 2:

(Refers to image 2)

Polyarthritis means five or more joints are affected by arthritis.1 It's most often associated with autoimmune diseases such as rheumatoid arthritis (RA), and certain viral infections can also trigger it.

Clinical Manifestations of Juvenile Idiopathic Arthritis

Joint Involvement

Joint involvement is a prominent effect of Juvenile Idiopathic Arthritis (JIA). The severity of joint involvement can differ among individuals with JIA, depending on the specific subtype (discussed in section subtypes) and disease activity.

JIA can affect joints of many sizes. The most commonly involved joints include the knees, ankles, wrists, elbows, and small joints of the hands and feet. However, any joint can be affected. Furthermore, joint involvement in JIA can be symmetrical or asymmetrical. Symmetrical involvement refers to the presence of arthritis in the same joints on both sides of the body, such as both knees or both wrists. Asymmetrical involvement means that the arthritis affects different joints on either side of the body. The affected joints in JIA typically exhibit signs of inflammation, including swelling, warmth, redness, and tenderness. Joint pain, stiffness, and limited range of motion are common symptoms. Children may experience difficulty with activities such as walking, running, writing, or gripping objects due to joint involvement. Many children with JIA experience morning stiffness, which refers to joint stiffness and reduced mobility upon waking up or after periods of rest. Morning stiffness typically improves with activity and movement throughout the day.

Image 3:

(Refers to image 3)

Certain features of JIA will depend on the age of the child affected (e.g. involvement of epiphyseal growth plates, early physeal fusion or the development of discrepancies in limb length).

3.2 Extra-Articular Manifestations

Juvenile Idiopathic Arthritis (JIA) is not limited to joint inflammation, as it can also involve various extra-articular manifestations. Extra-articular manifestations refer to symptoms and complications that occur outside the joints. These manifestations can affect different organ systems and have a significant impact on the overall health and well-being of children with JIA. Such include but are not limited to uveitis, rheumatoid nodules, fever, rash, growth abnormalities, anemia, and cardiac abnormalities.

1. Uveitis: Uveitis is a form of eye inflammation. It affects the middle layer of tissue in the eye wall (uvea).The signs, symptoms and characteristics of uveitis may include eye redness, eye pain, light sensitivity, blurred vision, floating spots in your field of vision(floaters), and decreased vision. There are multiple different types of uveitis. Anterior uveitis affects the inside of the front of your eye (between the cornea and the iris) and the ciliary body. It is also called iritis and is the most common type of uveitis. Intermediate uveitis affects the retina and blood vessels just behind the lens (pars plana) as well as the gel in the center of the eye (vitreous). Posterior uveitis affects a layer on the inside of the back of your eye, either the retina or the choroid. Panuveitis occurs when all layers of the uvea are inflamed, from the front to the back of your eye. (Image 4)

2. Rheumatoid Nodules: Rheumatoid nodules are firm lumps under the skin. They tend to form close to joints in people affected by rheumatoid arthritis. Although most of the time rheumatoid nodules are harmless, they can induce pain if located near a nerve or if there’s an underlying inflammation or sore. (Image 5)

3. Fever and Systemic Symptoms: Systemic-onset JIA, also known as Still's disease, is characterized by daily spiking fevers that last for at least two weeks and systemic symptoms such as fatigue, malaise, weight loss, and lymphadenopathy (enlarged lymph nodes). These systemic symptoms can affect overall health and quality of life.

4. Rash: Some children with JIA may develop a characteristic rash. The rash is typically salmon-pink in color, non-itchy, and evanescent. (Image 1)

5. Growth Abnormalities: JIA, especially when active and uncontrolled, can affect normal growth and development. Children may experience growth retardation, delayed puberty, and skeletal abnormalities, including limb length discrepancy. (image 3)

6. Anemia: Anemia, a decrease in the number of red blood cells, can occur in JIA due to chronic inflammation and reduced production of red blood cells. Anemia can lead to fatigue, weakness, and decreased exercise tolerance.

7. Cardiac and Pulmonary Involvement: Although less common, JIA can involve the heart and lungs. Pericarditis and pleuritis can occur in some cases, leading to chest pain, shortness of breath, and other cardiac or pulmonary symptoms. (Image 6)

Image 4:

(Refers to Image 4) A study shows triggering lifestyle factors associated with instances of acute anterior uveitis.

Image 5:

(Refers to Image 5) This image portrays rheumatoid nodules - lumps under the skin. 

Image 6:

(Refers to Image 6) In some cases, juvenile idiopathic arthritis can involve the heart. One of the worst outcomes could be heart failure, although unlikely.

3.3 Growth and Developmental Issues

 JIA is associated with multiple complications that could result in short-term or long-term disabilities and be detrimental to quality of life. Growth and pubertal disorders play an important role. Chronic inflammatory conditions are often associated with growth failure (image 7) ranging from slight decrease in height velocity to severe forms of short stature. The prevalence of short stature in JIA varies from 10.4% in children with polyarticular disease to 41% of patients with the systemic form, while oligoarthritis may lead to limb dissymmetry. The pathogenesis of growth disorders is multifactorial and includes the role of chronic inflammation, long-term use of corticosteroids, undernutrition, altered body composition, delay of pubertal onset or slow pubertal progression.. Although new therapeutic options are available to control inflammation, there are still 10–20% of patients with severe forms of the disease who show continuous growth impairment, ending in a short final stature. Moreover, delayed puberty is associated with a reduction in the peak bone mass with the possibility of  future bone fragility.

`         Image 7:

(Refers to Image 7) Juvenile Idiopathic Arthritis (JIA) is accompanied by growth failure, mostly occurring due to chronic inflammation and use of corticosteroids for treatment. 

3.4 Impact on Quality of Life

• Physical Effects: JIA can cause joint pain, swelling, stiffness, and mobility limitations. The severity can vary from mild joint discomfort to severe disability. In severe cases, it can affect growth and development (image 7), leading to deformities and functional limitations.

• 
  

• Emotional and Psychological Impact: Chronic pain and the limitations caused by 

• JIA can have a significant emotional impact on juveniles and adolescents. It may lead to negative feelings such as depression. 

• 
  

• Social Impact: JIA can affect a child's ability to participate in physical activities and sports, which can impact their social life and self-esteem. Therefore, the child may feel discouraged and left out from everyday activities.

• 
  

• Educational Impact: Absences due to doctor's appointments, hospitalizations, or pain can disrupt a child's education. They may need special accommodations or support at school to keep up with their peers. In my little sister’s case, constant blood works and rheumatologist appointments interrupted her education, requiring extra money spent into additional services.

• 
  

• Treatment Impact: The treatment for JIA often involves medications, such as anti-inflammatory nonsteroidal medication and in more extreme cases steroidal medication. These treatments can have side effects (such as immune system deficiency), and the child may need to make frequent visits to healthcare providers, which can be time-consuming and emotionally taxing.

• 
  

Diagnosis of Juvenile Idiopathic Arthritis

4.1 Diagnostic Criteria

In order to be diagnosed with juvenile rheumatoid arthritis, a child must have started showing symptoms before the age of 16 or 17 years old. Children as young as two years old can be diagnosed with juvenile rheumatoid arthritis.

When diagnosing a child with juvenile rheumatoid arthritis, the symptoms must be consistent with rheumatoid arthritis. Other tests and examinations can be done to further help support the diagnosis, however, doctors look for the distinct early warning signs. These early signs and symptoms include:

• Persistent joint swelling

• Consistent complaints of joint pain

• Joint pain primarily in hands, wrists and knees

• Appearance of skin rashes (Image 1)

• Swollen lymph nodes 

• Development of a limp

• Loss of motor skill function

• Anterior Uveitis (Image 4)

First, the doctor will conduct a physical exam, and locate relevant symptoms.

Next, the doctor will conduct a series of blood tests to further diagnose and gain additional information on JIA. There are a number of different blood tests that may be conducted to help identify juvenile rheumatoid arthritis. The blood tests doctors use to help diagnose juvenile rheumatoid arthritis include:

• Rheumatoid factor (RF)

• Anti-Cyclic Citrullinated Peptide (CCP)

• Erythrocyte Sedimentation Rate (ESR)

• C-Reactive Protein (CRP)

• Antinuclear Antibody (ANA)

Finally, the doctor will look for applicable family history. Juvenile rheumatoid arthritis is rare, and so it is unlikely that multiple family members will be diagnosed with it. All the same, family history of any sort of autoimmune disorder could potentially increase the likelihood of developing juvenile rheumatoid arthritis. If the child has a family member with an autoimmune disorder it could further support a diagnosis. It could indicate the child could have also developed an autoimmune disorder such as juvenile rheumatoid arthritis. 

4.2 Differential Diagnosis

Juvenile Idiopathic Arthritis or arthritis-like symptoms may be present in many other conditions (Image 8). It is important to consider differential diagnoses for JIA that include infections, other connective tissue diseases (myositis), and malignancies. Leukemia and septic arthritis are the most important diseases that can be mistaken for JIA. 

(Refers to Image 8) Shown on the left are different diagnoses that may be confused with that of Juvenile Idiopathic Arthritis.

Treatment Options for Juvenile Idiopathic Arthritis

 Pharmacological Interventions

5.1.1 Non-Steroidal Anti-Inflammatory Drugs

Nonsteroidal anti-inflammatory agents are a group of medicines that relieve pain and fever and reduce inflammation. All nonsteroidal anti-inflammatory work in the same way, and that is by blocking a specific group of enzymes called cyclo-oxygenase enzymes. These enzymes are responsible for the production of prostaglandins. Prostaglandins are a group of compounds with hormone-like effects that control many different processes such as inflammation, blood flow, and the formation of blood clots.

5.1.2 Disease-Modifying Anti-Rheumatic Drugs

Disease-modifying antirheumatic drugs are a group of medications that decrease inflammation and pain. They are often called immunosuppressants because these medications hold back or change how your immune system works. Disease-modifying antirheumatic drugs are utilized to decrease pain and inflammation, reduce/prevent joint damage, reduce bone erosion, undermine the spread of disease, and preserve joint function.

5.1.3 Biologic Agents

Biologic agents, also known as biologics or biologic response modifiers, have revolutionized the treatment of Juvenile Idiopathic Arthritis (JIA), especially for children and adolescents who do not respond well to traditional therapies. These medications target specific molecules and pathways in the immune system responsible for inflammation. Here are some biologic agents commonly used in the treatment of JIA:

• Etanercept (Enbrel): Etanercept is a tumor necrosis factor (TNF) inhibitor. It blocks the action of TNF, a protein involved in the inflammatory process. It is often used for various subtypes of JIA, including polyarticular JIA.

• Adalimumab (Humira): Adalimumab is another TNF inhibitor. It is approved for the treatment of polyarticular JIA and is administered by subcutaneous injection.

• Infliximab (Remicade): Infliximab is also a TNF inhibitor but is administered through intravenous infusion. It is used when other medications have not been effective, especially in children with severe JIA.

• Abatacept (Orencia): Abatacept works by inhibiting the activation of T cells in the immune system. It is used for the treatment of polyarticular JIA and systemic JIA.

• Tocilizumab (Actemra): Tocilizumab targets the interleukin-6 (IL-6) receptor, which plays a role in inflammation. It is approved for the treatment of polyarticular and systemic JIA.

• Anakinra (Kineret): Anakinra is an IL-1 receptor antagonist used primarily for systemic JIA. It blocks the action of IL-1, which is involved in the inflammation seen in this subtype.

• Canakinumab (Ilaris): Canakinumab is another IL-1 inhibitor, and it is also used to treat systemic JIA when other treatments have not been effective.

• Rituximab (Rituxan): Rituximab targets B cells, which are involved in the autoimmune response. It may be considered in refractory cases of JIA.

• Secukinumab (Cosentyx): Secukinumab is an IL-17A inhibitor used to treat enthesitis-related arthritis, a subtype of JIA that primarily affects the entheses (the areas where tendons and ligaments attach to the bone).

5.1.4 Corticosteroids

Corticosteroids, often simply referred to as steroids, are a class of medications that mimic the effects of naturally occurring hormones produced by the adrenal glands, specifically glucocorticoids. They have a wide range of pharmacological actions and are used for various medical purposes. Here are some key points about corticosteroids:

• Corticosteroids are well-known for their potent anti-inflammatory and immunosuppressive properties. They work by suppressing the immune system's response to inflammation and allergens, reducing the production of inflammatory substances, and inhibiting the activity of immune cells involved in the inflammatory process. However, corticosteroids have multiple adverse side effects (Image 9).

(Refers to Image 9) This image shows a few side effects of corticosteroids. 

Non-Pharmacological Interventions

5.2.1 Physical Therapy and Rehabilitation

Physical therapy can help you get moving safely and effectively. Physical therapists are licensed professionals with graduate degrees and clinical experience who examine, diagnose and treat or help prevent conditions that limit the body's ability to move and function in daily life. The physical therapist will assist and improve the mobility and restoration of affected joints, strength to support the joints, and the ability to perform every-day activities.

5.2.2 Occupational Therapy

An occupational therapist can teach you proper ergonomic principles and joint protection techniques, including how to hold, carry and use your joints during a task, such as using your whole arms and upper body to twist a doorknob rather than twisting it with just your wrist. Providing tips to pain management and pacing your activity to avoid added pain and fatigue, as well as training you how to use assistive devices is also under an occupational therapist’s purview. They can also teach you how to adapt the task or modify the environment to your abilities. Furthermore, an occupational therapist can assign orthotics. While often associated with shoe inserts placed in the footbed of a shoe to increase a shoe’s comfort, orthotics are not limited to the foot or strictly for comfort. Essentially an orthosis is a wearable assistive device that helps correct musculoskeletal alignment of a joint. An occupational therapist can make and custom fit an orthotic tailored to your joints to help reduce pain and further destruction or deformity of a joint while also increasing function of that joint. Orthoses are often prescribed to allow a joint to rest at nighttime to help decrease inflammation.

Conclusion

In conclusion, Juvenile Idiopathic Arthritis (JIA) is a complex and challenging condition that significantly impacts the lives of affected children and their families. This research paper has provided a comprehensive overview of JIA, including its prevalence, classification, clinical manifestations, diagnosis, and treatment options. JIA is not limited to joint inflammation; it can involve various extra-articular manifestations, affecting multiple organ systems. The diagnosis of JIA relies on a combination of clinical symptoms, physical examinations, and laboratory tests, and it is crucial to differentiate it from other conditions with similar symptoms. While there is no cure for JIA, this paper has highlighted various pharmacological and non-pharmacological interventions aimed at suppressing symptoms, preventing joint damage, and improving the quality of life for affected individuals. It is my hope that this research paper contributes to raising awareness about JIA and empowers healthcare providers and families with valuable information to better manage this chronic condition and support the children living with it.

References:

1. Bansal, Nancy, et al. “A Comprehensive Overview of Juvenile Idiopathic Arthritis: From Pathophysiology to Management.” Autoimmunity Reviews, vol. 22, no. 7, 1 July 2023, p. 103337, www.sciencedirect.com/science/article/abs/pii/S156899722300071X, https://doi.org/10.1016/j.autrev.2023.103337.

2. Mayo Clinic . “Rheumatoid Arthritis - Symptoms and Causes.” Mayo Clinic, 25 Jan. 2023, www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/symptoms-causes/syc-20353648.‌

3. “Rheumatoid Arthritis Prevalence: Statistics, Causes, and Risk Factors.” Www.medicalnewstoday.com, 12 July 2022, www.medicalnewstoday.com/articles/rheumatoid-arthritis-prevalence#how-common-is-ra.

4. ‌“100 Arthritis Statistics You Should Know.” LIVESTRONG.COM, www.livestrong.com/article/13731496-arthritis-statistics/.

‌5. “Juvenile Idiopathic Arthritis (JIA) (for Teens) - Nemours KidsHealth.” Kidshealth.org, kidshealth.org/en/teens/juv-rheumatoid-arthritis.html.

6. ‌“Juvenile Idiopathic Arthritis: Symptoms, Causes, Treatments.” Cleveland Clinic, my.clevelandclinic.org/health/diseases/10370-juvenile-idiopathic-arthritis#:~:text=If%20it%20is%20not%20treated%2C%20JIA%20can%20lead. Accessed 20 Jan. 2024.

7. “Immunosuppression (Weak Immune System).” Patient.info, 25 Oct. 2023, patient.info/allergies-blood-immune/immune-system-diseases/immune-suppression#nav-7. Accessed 20 Jan. 2024.

8. “Systemic Juvenile Idiopathic Arthritis.” Www.arthritis.org, www.arthritis.org/diseases/systemic-juvenile-idiopathic-arthritis.

9. Ravelli, Angelo, and Alberto Martini. “Juvenile Idiopathic Arthritis.” The Lancet, vol. 369, no. 9563, Mar. 2007, pp. 767–778, www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)60363-8/fulltext, https://doi.org/10.1016/s0140-6736(07)60363-8.

10. ‌“Juvenile Idiopathic Arthritis | DermNet.” Dermnetnz.org, dermnetnz.org/topics/juvenile-idiopathic-arthritis#:~:text=Cutaneous%20involvement%20is%20one%20of%20t. Accessed 20 Jan. 2024.

‌11. “UpToDate.” Www.uptodate.com, www.uptodate.com/contents/polyarticular-juvenile-idiopathic-arthritis-clinical-manifestations-diagnosis-and-complications#. Accessed 20 Jan. 2024.

‌12. “For Patients and Families.” Www.hopkinsmedicine.org, www.hopkinsallchildrens.org/Patients-Families/Health-Library/HealthDocNew/Polyarticular-Juvenile-Idiopathic-Arthritis. Accessed 20 Jan. 2024.

‌13. “Pediatrics Notes: Clinical Manifestations of Juvenile Rheumatoid Arthritis.” Pediatrics Notes, 1 Nov. 2017, pediatricsnotes.blogspot.com/2017/11/clinical-manifestations-of-juvenile.html. Accessed 20 Jan. 2024.

14. “Juvenile Idiopathic Arthritis.” Physiopedia, www.physio-pedia.com/Juvenile_Idiopathic_Arthritis.

‌15. “Uveitis - Symptoms and Causes.” Mayo Clinic, 2018, www.mayoclinic.org/diseases-conditions/uveitis/symptoms-causes/syc-20378734.

16. Bruce, Debra Fulghum, and PhD. “What Are Rheumatoid Nodules? Causes and Treatments.” WebMD, www.webmd.com/rheumatoid-arthritis/guide/rheumatoid-nodules.

‌17. Aghjayan, Rita. “New Episodes of Recurrent Acute Anterior Uveitis Linked to Stress, Sleeplessness.” Medical Bag, 2 Aug. 2021, www.medicalbag.com/home/news/new-episodes-of-recurrent-acute-anterior-uveitis-linked-to-stress-sleeplessness-2/. Accessed 20 Jan. 2024.

18. ‌“Hands with Rheumatoid Arthritis by James Stevenson/Science Photo Library.” Fine Art America, fineartamerica.com/featured/hands-with-rheumatoid-arthritis-james-stevensonscience-photo-library.html. Accessed 20 Jan. 2024.

‌19. Schwartz, Thomas, et al. “Cardiac Involvement in Adult and Juvenile Idiopathic Inflammatory Myopathies.” RMD Open, vol. 2, no. 2, Sept. 2016, p. e000291, rmdopen.bmj.com/content/rmdopen/2/2/e000291.full.pdf, https://doi.org/10.1136/rmdopen-2016-000291. Accessed 24 Oct. 2020.

‌20. D’Angelo, Debora Mariarita, et al. “Growth and Puberty in Children with Juvenile Idiopathic Arthritis.” Pediatric Rheumatology Online Journal, vol. 19, 12 Mar. 2021, www.ncbi.nlm.nih.gov/pmc/articles/PMC7953722/, https://doi.org/10.1186/s12969-021-00521-5.

21. “JRA Diagnosis: What Is the Criteria for Diagnosis of Juvenile RA? - RheumatoidArthritis.org.” Https://Www.rheumatoidarthritis.org/, www.rheumatoidarthritis.org/ra/juvenile/diagnosis/.

‌22. Kim, Young Dae, et al. “Differential Diagnosis of Juvenile Idiopathic Arthritis.” Journal of Rheumatic Diseases, vol. 24, no. 3, 2017, p. 131, synapse.koreamed.org/Synapse/Data/PDFData/1010JRD/jrd-24-131.pdf, https://doi.org/10.4078/jrd.2017.24.3.131. Accessed 30 Apr. 2020.

‌23. Goldmuntz, Ellen A., and Patience H. White. “Juvenile Idiopathic Arthritis”: Pediatrics in Review, vol. 27, no. 4, 1 Apr. 2006, pp. e24–e32, https://doi.org/10.1542/pir.27.4.e24. Accessed 14 Apr. 2022.

‌24. Drugs.com. “Nonsteroidal Anti-Inflammatory Drugs.” Drugs.com, Drugs.com, 2018, www.drugs.com/drug-class/nonsteroidal-anti-inflammatory-agents.html.

25. ‌“Disease-Modifying Antirheumatic Drugs (DMARDS).” Cleveland Clinic, my.clevelandclinic.org/health/drugs/22683-dmards.

‌26. “Corticosteroid Side Effects.” RxNotes, 12 Mar. 2019, rxnotes.ca/side-effects/corticosteroid-side-effects/. Accessed 20 Jan. 2024.

27. Arthritis Foundation. “Physical Therapy for Arthritis | Arthritis Foundation.” Www.arthritis.org, www.arthritis.org/health-wellness/treatment/complementary-therapies/physical-therapies/physical-therapy-for-arthritis.

28. “The Benefits of Occupational Therapy.” Www.arthritis.org, www.arthritis.org/health-wellness/treatment/complementary-therapies/physical-therapies/the-benefits-of-occupational-therapy.